Ing. Martina Almáši, Ph.D.
Researcher, Biobank and CELSPAC Laboratories
Correspondence Address:
Kotlářská 267/2, 611 37 Brno
Phone: | +420 532 23 2633 |
---|---|
E‑mail: |
social and academic networks: |
---|
Total number of publications: 34
2016
-
Clonal cytogenetics changes in progression of multiple myeloma to extramedullary relapse and plasmocellular leukemia: a case report
International Journal of Clinical and Experimental Pathology, year: 2016, volume: 9, edition: 1
-
Genomewide profiling of copy-number alteration in monoclonal gammopathy of undetermined significance
European Journal of Haematology, year: 2016, volume: 97, edition: 6, DOI
2015
-
Banky biologického materiálu
Molekulární medicína, year: 2015, number of pages: 3 s.
-
Combination of serum microRNA-320a and microRNA-320b as a marker for Waldenström macroglobulinemia
American Journal of Hematology, year: 2015, volume: 90, edition: 3, DOI
-
Extramedullary relapse of multiple myeloma defined as the highest risk group based on deregulated gene expression data
Biomedical Papers of the Faculty of Medicine of Palacký University, Olomouc, Czech Republic, year: 2015, volume: 159, edition: 2, DOI
-
Monoklonalní gamapatie nejasného významu s nízkým a vysokým stupněm rizika: výstupy z analýz RMG registru České myelomové skupiny pro praxi
Klinická biochemie a metabolismus, year: 2015, volume: 23, edition: 2
-
Potenciál volné cirkulující DNA v diagnostice nádorových onemocnění
Klinická onkologie, year: 2015, volume: 28, edition: 4
2014
-
Genome-Wide Screening of Cytogenetic Abnormalities in Multiple Myeloma Patients Using Array-CGH Technique: A Czech Multicenter Experience
BioMed Research International, year: 2014, volume: Neuveden, edition: MAY, DOI
2013
-
Association of SNPs in P-glycoprotein 1 with Longer Time to Event in Bortezomib-treated Multiple Myeloma Patients
Year: 2013, type: Conference abstract
-
Gain(1)(q21) is an Unfavorable Genetic Prognostic Factor for Patients With Relapsed Multiple Myeloma Treated With Thalidomide but Not for Those Treated With Bortezomib
Clinical lymphoma, myeloma & leukemia, year: 2013, volume: 13, edition: 2, DOI